TrialCancer medicine2019

Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.

Emilie Charton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.